Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The History of Treating Lupus with Hydroxychloroquine

Ruth Jessen Hickman, MD  |  Issue: June 2020  |  June 15, 2020

Dr. Esdaile

Dr. Esdaile

Dr. Esdaile, who trained nearby at Yale University, spoke to Dr. Rothfield in detail about the work. He coordinated the study out of Montreal General Hospital, Quebec, Canada, where he was working at the time. He recruited doctors from two other hospitals in Montreal, from a hospital in Ottawa and from another in Hamilton, Ontario. Those physicians then asked their colleagues to send them any lupus patients who were doing well and currently taking hydroxychloroquine.

“The fact that the Canadians banded together to do this is a remarkable substory of this paper,” says Dr. Petri. “They are lumped together as the Canadian Hydroxychloroquine Study Group. This is a great example of clinicians caring about lupus and not caring about their own names or their own egos.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Study Design & Outcomes

Dr. Esdaile and colleagues opted to perform a prospective, double-blind, randomized withdrawal study to examine the potential protective role of hydroxy­chloroquine in preventing disease flares.

The group studied lupus patients who had been taking hydroxychloroquine in doses ranging from 100 mg to 400 mg per day. The average length of time the lupus patients had been taking hydroxy­chloroquine was three years, and all patients had taken it for at least six months. All had experienced clinical remission or only minimal disease activity for the three months prior to study initiation. The patients were randomized to either continue taking hydroxychloroquine at their current dose or to take a placebo.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Esdaile explains the characteristics of lupus make it challenging to study. He partly chose the withdrawal design because lupus often requires intensive intervention with stronger drugs, such as prednisone for flares of disease activity. He believed the effect of that would obscure the impact of hydroxychloroquine, making benefits harder to see.

In 2016, the American Academy of Ophthalmology published guidelines for hydroxychloroquine patient monitoring, recommending optical coherence tomogram at baseline, five years thereafter & then every year following for patients without major risk factors for retinopathy. … In terms of toxicity, recent guidelines … recommend lowering the dosage from 6.5 mg/kg patient weight to less than 5.0 mg/kg.

“If you used people who had never seen hydroxychloroquine, the flare would create a nightmare for analysis,” he says. “Whereas the way we designed it, the flareup was the outcome.” Additionally, because many doctors and patients had concerns about taking the drug continuously, Dr. Esdaile says it would have been more difficult to find patients to enroll in a trial of patients naive to hydroxychloroquine.

Blinding the study properly was a challenge, because hydroxychloroquine formulations at the time had a strong, unpleasant taste. Dr. Esdaile worked with the drug manufacturer to obtain a drug and a placebo in identical shapes. To help with the disguise, the placebos were coated with a trace amount of hydroxychloroquine (<1 mg), so they would also have an unpleasant taste.

The group assessed patients every four weeks over a 24-week period using standard clinical assessments and laboratory tests. Final analyses included 47 patients with lupus.1 Using data from Dr. Rothfield’s work, Dr. Esdaile and colleagues estimated that staying on hydroxychloroquine would reduce flares by about 50% with their study design.

Dr. Esdaile and colleagues found the relative risk of a clinical flare-up (the primary outcome) was 2.5 times higher in patients taking placebo than in those who had continued to take hydroxychloroquine. Moreover, the relative risk of the secondary outcome, severe disease exacerbation, was six times higher in patients taking placebo than in those who had continued taking hydroxychloroquine. (This, however, did not reach statistical significance, which was unsurprising given study size and length.)

The findings also provided early evidence that hydroxychloroquine treatment might reduce nephritic flares successfully. Efforts to properly blind the study were successful, with only 53% of participants correctly guessing whether they were taking hydroxychloroquine or placebo.1

“It was a remarkably simple study, and the preventive role of hydroxychloroquine was so strong,” Dr Petri remarks. She contrasts the sample size with those found in modern studies using much higher numbers of patients. She adds, “I often say if something really works, you don’t need a lot of patients to show it. And that’s one reason why I think this is such a wonderful study.”

The randomized withdrawal trial design is now only rarely used in lupus, although it is still sometimes employed in juvenile chronic arthritis studies. Dr. Petri says, “I think this shows that maybe we’ve forgotten it’s a good study design.”

Randomized withdrawal trials do present problems of generalizability. For example, such a trial design excludes patients who had previously discontinued hydroxychloroquine due to lack of response, toxicity or other factors, and thus may tend to overestimate efficacy.

But Dr. Esdaile emphasizes that one of the design’s strengths is the ability to show an effect with a smaller sample size.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lost & Foundretinopathy

Related Articles

    Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine

    November 16, 2016

    Both due to its efficacy and favorable side effect profile when compared with alternative drugs for rheumatologic conditions, hydroxychloroquine is an important agent in rheumatologists’ armamentarium. However, one barrier to hydroxychloroquine use can be its effects on the eye (also see “Revised Retinopathy Screening Guidelines,”). Ocular side effects of hydroxychloroquine can include impact on the…

    Are We Making Progress in Treating Lupus? Clinical Insights from Dr. Michelle Petri

    November 1, 2023

    At the 19th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases course, Dr. Michelle Petri gave a presentation concerning the overall state of lupus treatment outcomes in the U.S.

    Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?

    February 13, 2020

    The Johns Hopkins Lupus Center, Baltimore, has described its experience using hydroxychloroquine (HCQ) levels.1 Forty-four percent of its patients had levels below 500 ng/mL (partial nonadherence); 13% were severely nonadherent (<200 ng/mL). They were shown their results and educated on HCQ adherence. Adherence then improved to 80%; those with lower HCQ levels had higher disease…

    Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus

    February 18, 2019

    CHICAGO—The correct dosing of hydroxychloroquine (HCQ) for systemic lupus erythematosus (SLE) is a concern of all rheumatologists. Petros Efthimiou, MD, clinical professor of medicine at New York University, New York City, opened the Great Debate of the 2018 ACR/ARHP Annual Meeting by stating, “Today, we will be discussing a critical clinical problem that affects everyone’s…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences